(Q79165142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

main subject

cardiovascular disease

1 reference

1 reference

Haruo Nakamura

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Kikuo Arakawa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Hiroshige Itakura

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Akira Kitabatake

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Yoshio Goto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Takayoshi Toyota

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Noriaki Nakaya

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Shoji Nishimoto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Masaharu Muranaka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Akira Yamamoto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Kyoichi Mizuno

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Yasuo Ohashi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

MEGA Study Group

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

9542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

1155-1163

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Trend of coronary heart disease and its relationship to risk factors in a Japanese population: a 26-year follow-up, Hiroshima/Nagasaki study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969472-5

7 January 2021

10.1016/S0140-6736(06)69472-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17011942%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference